Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes

Current Atherosclerosis Reports

Volumn 10, Issue 2, 2008, Pages 106-116

  Bourassa, Martial G ^a   Berry, Colin ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICOTINIC ACID; PERINDOPRIL; PIOGLITAZONE; PLACEBO; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TORCETRAPIB;

AEROBIC EXERCISE; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIET THERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FRACTURE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POTASSIUM BLOOD LEVEL; PREVALENCE; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 41749098308     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0016-0     Document Type: Review

References (50)

1. Berry C, Tardif JC, Bourassa MG: Coronary heart disease in patients with diabetes. Part I: recent advances in prevention and non-invasive management. J Am Coll Cardiol 2007, 49:631-642.
2. American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care 2006, 29(Suppl 1):S4-S42.
3. Lichtenstein AH, Appel LJ, Brands M, et al.: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006, 114:82-96.
4. Buse JB, Ginsberg HN, Bakris GL, et al.: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126.
5. Nathan DM, Buse JB, Davidson MB, et al.: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006, 29:1963-1972.
6. Poirier P, Giles TD, Bray GA, et al.: Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898-918.
7. Kavey RE, Allada V, Daniels SR, et al.: Cardiovascular risk reduction in high-risk pediatric patients. A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood pressure Research, cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation 2006, 114:2710-2738.
8. Sigal RJ, Kenny GP, Wasserman DH, et al.: Physical activity/exercise and type 2 diabetes. A consensus statement from the American Diabetes Association. Diabetes Care 2006, 29:1433-1438.
9. Lipscombe LL, Hux JE: Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007, 369:750-756.
10. Jones LR, Wilson CI, Wadden TA: Lifestyle modification in the treatment of obesity: an educational challenge and opportunity. Clin Pharmacol Ther 2007, 81:776-779.
11. Eckel RH, Kahn R, Robertson RM, Rizza RA: Preventing cardiovascular disease and diabetes. A call to action from the American Diabetes Association and the American Heart Association. Diabetes Care 2006, 29:1697-1699.
12. Lorenzo C, Williams K, Hunt KJ, Haffner SM: The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007, 30:8-13.
13. Booth GL, Kapral MK, Fung K, Tu JV: Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006, 368:29-36.
14. Knopp RH, D'Emden M, Smilde JG, Pocock SJ, on behalf of the ASPEN Study Group: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. The Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin dependent diabetes mellitus (ASPEN). Diabetes Care 2006, 29:1478-1485.
15. Donahoe SM, Stewart GC, McCabe CH, et al.: Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298:765-775.
16. Wang J, Ruotsalainen S, Moilanen L, et al.: The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007, 28:857-864.
17. Mozaffarian D, Marfisi RM, Levantesi G, et al.: Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007, 370:667-675.
18. The DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-1562.
19. The DREAM Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-1105.
20. Ratner RE, for the Diabetes Prevention Program Research Group: An update on the diabetes prevention program. Endocr Pract 2006, 12:20-24.
21. Chiasson JL: Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006, 12(Suppl 1):25-30.
22. Aronne LJ: Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007, 120:S26-S34.
23. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.; RIO-North America Study Group: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
24. Zinman B, Harris SB, Gerstein HC, et al.: Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes Obes Metab 2006, 8:531-537.
25. Wexler DJ, Meigs JB, Cagliero E, et al.: Prevalence of hyper-and hypoglycemia among inpatients with diabetes: anational survey of 44 U.S. hospitals. Diabetes Care 2007, 30:367-369.
26. Vasudevan AR, Burns A, Fonseca VA: The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat Endocrinol 2006, 5:273-286.
27. The Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. One-year results of the Look AHEAD trial. Diabetes Care 2007, 30:1374-1383.
28. Scheen AJ, Finer N, Hollander P, et al.; for the RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006, 368:1660-1672.
29. Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA 2006, 296:2572-2581.
30. Khan SE, Haffner SM, Heise MA, et al.; for the ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
31. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007, 357:28-38.
32. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99(12A):21i-33i.
33. Magee MF, Isley WL; BARI 2D Trial Investigators: Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol 2006, 97:20G-30G.
34. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
36. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA 2007, 298:1189-1195.
37. Kendall C, Wooltorton E: Rosiglitazone (Avandia) and macular edema. Can Med Assoc J 2006, 174:623.
38. Shepherd J, Barter P, Carmena R, et al.; for the Treating to New Targets Investigators: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets study. Diabetes Care 2006, 29:1220-1226.
39. Nissen SE, Tardif JC, Nicholls SJ, et al.; ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316.
40. Ginsberg HN, Bonds DE, Lovato LC, et al.; for the ACCORD Study Group: Evolution of the lipid trial protocol of the Action to Control Cardiovascual Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99(Suppl):56i-67i.
41. Lachin JM, Christophi CA, Edelstein SL, et al.: Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007, 56:1153-1159.
42. Poirier P, Després JP, Bertrand OF: Identifying which patients with diabetes should be tested for the presence of coronary artery disease-the importance of baseline electrocardiogram and exercise testing. Can J Cardiol 2006, 22:9A-15A.
43. Albers AR, Krichavsky MZ, Balady GJ: Stress testing in patients with diabetes mellitus. Diagnostic and prognostic value. Circulation 2006, 113:583-592.
44. Patel A; ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007, 370:829-840.
45. Anselmino M, Bartnik M, Malmberg K, Ryden L, on behalf of the Euro Heart Survey Investigators: Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. Eur J Cardiovasc Prev Rehabil 2007, 14:28-36.
46. Hicks PC, Westfall JM, Van Vorst RF, et al.: Action or inaction? Decision making in patients with diabetes and elevated blood pressure in primary care. Diabetes Care 2006, 29:2580-2585.
47. Spann SJ, Nutting PA, Galliher JM, et al.: Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med 2006, 4:23-31.
48. Cushman WC, Basile J: Achieving blood pressure goals: why aren't we? J Clin Hypertens 2006, 8:865-872.
49. Yan AT, Yan RT, Tan M, et al.; for the Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators: Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006, 119:676-683.
50. Bhatt DL, Steg PG, Ohman EM, et al.: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295:180-189.